{"url_path":"/sec/crvs/8-k/2026-06-12/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-12","source_url":"https://www.sec.gov/Archives/edgar/data/1626971/0001171843-26-004094-index.html","accession_number":"0001171843-26-004094","cik":"0001626971","ticker":"CRVS","issuer_name":"Corvus Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1626971/0001171843-26-004094-index.html","primary_entity_key":"0001626971","primary_entity_name":"Corvus Pharmaceuticals, Inc."},"word_count":371,"has_tables":true,"body_markdown":"**Item 5.07 Submission of Matters to a Vote of Security Holders.**\n\nOn June 11, 2026, Corvus Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual\nMeeting of Stockholders (the “Annual Meeting”). Only stockholders of record at the close of business on April 16, 2026, the\nrecord date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, there were 84,090,424 shares of\nthe Company’s common stock outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 73,021,854 shares of the\nCompany’s common stock were voted in person or by proxy for the three proposals set forth below, each of which is described in the\nCompany’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026.\n\n \n\nThe tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as\nfollows:\n\n \n\n**Proposal No. 1 — Election of Directors**\n\nThe Company’s stockholders elected the Class I director nominees below to the Company’s\nBoard of Directors to hold office until the 2029 Annual Meeting of Stockholders or until his or her respective successor is elected and\nqualified or appointed, or the earlier of his or her death, resignation or removal. \n\n \n\n**Class III Director Nominees  **\n \n**Votes For**\n \n**Votes Withheld**\n \n**Broker Non**-**Votes**\n\nRichard A. Miller, M.D.\n \n58,275,179\n \n2,697,052\n \n12,049,623\n\nLinda S. Grais, M.D., J.D.\n \n53,185,380\n \n7,786,851\n \n12,049,623\n\n** **\n\n**Proposal No. 2 — Ratification of Selection of Independent Registered Accounting\nFirm**\n\nThe Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent\nregistered public accounting firm of the Company for its fiscal year ending December 31, 2026.\n\n \n\n**Votes For**\n \n**Votes Against**\n \n**Abstain**\n\n72,864,335\n \n105,674\n \n51,845\n\n \n\n****\n\n**Proposal No. 3 —Non-Binding Advisory Vote to Approve the Compensation of the Company’s\nNamed Executive Officers**\n\nOn a non-binding advisory basis, the Company’s stockholders approved the compensation of the\nCompany’s named executive officers.\n\n \n\n**Votes For**\n \n**Votes Against**\n \n**Abstain**\n \n**Broker Non-Votes**\n\n58,936,532\n \n  1,971,370\n \n64,329\n \n12,049,623\n\n \n\n \n\n** **\n\n** **\n\n** **\n\n \n\n \n\n**SIGNATURES**\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as\namended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n**CORVUS PHARMACEUTICALS, INC.**\n\n \n \n \n\nDate: June 12, 2026\nBy:\n\n/s/ Leiv Lea\n\n \n \nLeiv Lea\n\n \n \nChief Financial Officer"}